Are you Dr. Rinehart?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 80 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
740 Rose St
Lexington, KY 40536Phone+1 859-323-5981Fax+1 859-257-6002
Summary
- Dr. John Rinehart, MD is an oncologist in Lexington, Kentucky. He is currently licensed to practice medicine in Kentucky, Alabama, and Texas. He is affiliated with Bourbon Community Hospital and is a Professor at Kentucky.
Education & Training
Ohio State University HospitalResidency, Internal Medicine, 1972 - 1974
University of ChicagoResidency, Internal Medicine, 1971 - 1972- Ohio State University HospitalInternship, Internal Medicine, 1970 - 1971
- Ohio State University College of MedicineClass of 1970
Certifications & Licensure
KY State Medical License 2004 - 2025
OH State Medical License 1970 - 2018
AL State Medical License 1999 - 2004
TX State Medical License 1991 - 2003- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- CI-1040 in Treating Patients With Advanced Breast, Colon, Pancreatic, or Non-Small Cell Lung Cancer Start of enrollment: 2002 Feb 01
- Randomized Phase 2 Trial of Pre-chemotherapy Leukine vs. Leukine-Dexamethasone in Combination With Gemzar & 5-FU in Patients With Metastatic Renal Cell Carcinoma Start of enrollment: 2005 Sep 01
- Randomized Phase II Trial of Doxil With or Without Dexamethasone for Metastatic Hormone Refractory Prostate Cancer Start of enrollment: 2005 Oct 01
- Join now to see all
Publications & Presentations
PubMed
- 482 citationsMulticenter Phase II Study of the Oral MEK Inhibitor, CI-1040, in Patients With Advanced Non-Small-Cell Lung, Breast, Colon, and Pancreatic CancerJohn J. Rinehart, Alex A. Adjei, Patricia Lorusso, David Waterhouse, J. Randolph Hecht
Journal of Clinical Oncology. 2004-11-15 - 188 citationsPhase I Pharmacokinetic and Pharmacodynamic Study of the Oral MAPK/ERK Kinase Inhibitor PD-0325901 in Patients with Advanced CancersPatricia LoRusso, Smitha S. Krishnamurthi, John J. Rinehart, Lisle Nabell, Lisa Malburg
Clinical Cancer Research. 2010-03-15 - 7 citationsLack of CNS Penetration of Docetaxel in a Patient with Leptomeningeal CarcinomatosisJ D Herrington, L. Di Nunno, John J. Rinehart
The Annals of Pharmacotherapy. 1998-05-01
Grant Support
- Dexamethasone/Carboplatin/Gemcitabine Untreated NsclcNational Center For Research Resources2004
- Core--Clinical TrialsNational Cancer Institute2000–2002
- Clinical Oncology Research Career Development ProgramNational Cancer Institute2000–2002
- Trial Of L-377202 Once Every Three WeeksNational Center For Research Resources2000
- Scott And White Community Clinical Oncology ProgramNational Cancer Institute1997
- Southwest Oncology GroupNational Cancer Institute1993–1997
- Chemotherapy And Biologics In A Murine Tumor ModelNational Cancer Institute1991
- Phase IB Trial Of IL-2 Alone Or With Cytotoxic CellsDivision Of Cancer Treatment1988–1990
Professional Memberships
- Member
